Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cognitive Dysfunction × Methylphenidate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Fatigue 4 Prostatic Neoplasms 3 Sleep Wake Disorders 2 Neurotoxicity Syndromes 1 Hematologic Neoplasms 1 Depression 1 Cognitive Dysfunction 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1

Interventions

Memantine 2 lithium sulfate 1 lime 1 XENP 1595 1 Ramipril 1 Methylphenidate 1 Lithium 1 Infliximab 1 Ibuprofen 1 Exercise 1 Cannabidiol 1 Behavior Therapy 1 Aspirin 1 Ashwagandha 1 Anticonvulsants 1 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡